DistantNews
Support us
Brazil's Lula begins preventive radiotherapy for skin cancer

Brazil's Lula begins preventive radiotherapy for skin cancer

From El País · () Spanish

Translated from Spanish, summarized and contextualized by DistantNews.

At a glance

News Official statement Ongoing story
  • Brazilian President Luiz Inácio Lula da Silva began preventive radiotherapy for a skin cancer lesion removed from his scalp.
  • The 15-session treatment will not affect his official agenda, according to his team.
  • The announcement comes four months before Brazil's general elections, where Lula is seeking a fourth term and leads in polls.

Brazilian President Luiz Inácio Lula da Silva has started a course of preventive radiotherapy for a skin cancer lesion removed from his scalp a month ago. The treatment, consisting of 15 superficial sessions, began Monday morning at a private hospital in Brasília.

According to a medical statement from the hospital, the decision for complementary treatment followed the "excision of a basal cell lesion on April 24, 2026." Each session lasts only two minutes. The president's team has assured the Brazilian press that the treatment will not interfere with his official duties.

Despite the health news, Lula continued with his work agenda, participating in a public event with Brazilian and African rectors. The 80-year-old president, who previously battled laryngeal cancer in 2011, is seeking a fourth term in office. The election is scheduled for October, with Lula currently leading opinion polls against his main right-wing challenger, Senator Flávio Bolsonaro.

Following the excision of a basal cell lesion on April 24, 2026, complementary treatment with superficial preventive radiotherapy of the scalp was opted for, which began this Monday.

— hospital medical statementannouncing the start of President Lula's radiotherapy treatment
DistantNews Editorial

Originally published by El País in Spanish. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.